Theriva Biologics Inc (TOVX)
1.28
+0.02
(+1.59%)
USD |
NYAM |
Nov 21, 16:00
1.28
0.00 (0.00%)
After-Hours: 20:00
Theriva Biologics Enterprise Value: -12.68M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -12.68M |
| November 20, 2024 | -12.74M |
| November 19, 2024 | -12.74M |
| November 18, 2024 | -12.80M |
| November 15, 2024 | -12.46M |
| November 14, 2024 | -12.49M |
| November 13, 2024 | -12.30M |
| November 12, 2024 | -12.27M |
| November 11, 2024 | -11.07M |
| November 08, 2024 | -10.71M |
| November 07, 2024 | -10.59M |
| November 06, 2024 | -11.09M |
| November 05, 2024 | -11.09M |
| November 04, 2024 | -10.83M |
| November 01, 2024 | -11.04M |
| October 31, 2024 | -12.42M |
| October 30, 2024 | -12.37M |
| October 29, 2024 | -12.40M |
| October 28, 2024 | -12.27M |
| October 25, 2024 | -12.24M |
| October 24, 2024 | -12.32M |
| October 23, 2024 | -12.40M |
| October 22, 2024 | -12.45M |
| October 21, 2024 | -12.37M |
| October 18, 2024 | -12.35M |
| Date | Value |
|---|---|
| October 17, 2024 | -12.45M |
| October 16, 2024 | -12.42M |
| October 15, 2024 | -12.61M |
| October 14, 2024 | -12.62M |
| October 11, 2024 | -12.29M |
| October 10, 2024 | -12.16M |
| October 09, 2024 | -11.93M |
| October 08, 2024 | -12.22M |
| October 07, 2024 | -11.98M |
| October 04, 2024 | -11.85M |
| October 03, 2024 | -11.56M |
| October 02, 2024 | -13.00M |
| October 01, 2024 | -12.90M |
| September 30, 2024 | -12.63M |
| September 27, 2024 | -11.31M |
| September 26, 2024 | -11.93M |
| September 25, 2024 | -11.48M |
| September 24, 2024 | -10.28M |
| September 23, 2024 | -10.06M |
| September 20, 2024 | -9.548M |
| September 19, 2024 | -9.562M |
| September 18, 2024 | -9.345M |
| September 17, 2024 | -9.142M |
| September 16, 2024 | -9.481M |
| September 13, 2024 | -9.196M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-41.16M
Minimum
Dec 22 2022
125.38M
Maximum
Mar 12 2021
-8.051M
Average
-12.44M
Median
Enterprise Value Benchmarks
| Merck & Co Inc | 276.21B |
| Pro-Dex Inc | 143.63M |
| BioCardia Inc | 4.858M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.726M |
| Total Expenses (Quarterly) | 5.036M |
| EPS Diluted (Quarterly) | -6.81 |
| Earnings Yield | -2.59K% |